Treatment progress of mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2019.12.006
- VernacularTitle: 套细胞淋巴瘤治疗进展
- Author:
Yimin REN
1
;
Wei XU
Author Information
1. Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
- Publication Type:Review
- Keywords:
Lymphoma, mantle-cell;
Lymphoma, non-Hodgkin;
Molecular targeted therapy;
Immunotherapy;
Chimeric antigen receptor T cell
- From:
Journal of Leukemia & Lymphoma
2019;28(12):724-727
- CountryChina
- Language:Chinese
-
Abstract:
Mantle cell lymphoma (MCL) is a subtype of aggressive B-cell non-Hodgkin lymphoma(NHL) with a heterogeneous clinical characteristics, accounting for 3%-10% of adult-onset NHL. With the great advance of novel drugs, the therapeutic options for MCL are constantly updating. The 61st American Society of Hematology Annual Meeting reported the recent treatment progress of MCL including novel drugs,combinations of nonchemotherapeutic agents and chimeric antigen receptor T-cell therapy. This paper focuses on the treatment progress of MCL.
